YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Good morning. Stocks were on track for their fourth day of declines on Thursday as investors watched long-dated bond yields amid surging oil prices ahead of this week's key inflation print. The market has been pricing in a 62% chance of a…
Tenaya Therapeutics, Inc. Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory…
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the…
(RTTNews) - Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, following the planned retirement of Hiro Higa, Senior V…
(RTTNews) - Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, said on Monday that it has appointed Eric Hyllengren as Chief Financial Officer with effect from July 13. Hyllengren most recently served as CFO of Zura…
SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the…
(RTTNews) - Tenaya Therapeutics, Inc. (TNYA) announced new interim data from its ongoing MyPEAK-1 Phase 1b/2 trial evaluating TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The results were…
(RTTNews) - Tenaya Therapeutics, Inc. (TNYA) announced that it will present new interim data today from Cohort 1 and Cohort 2 of the ongoing MyPEAK-1 Phase 1b/2 trial evaluating TN-201, its gene therapy for adults with MYBPC3-associated hy…
The market in the United States has been flat over the last week but is up 27% over the past year, with earnings forecast to grow by 17% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for comp…
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of TN-401 Activity in He…
The United States market has shown a robust performance, climbing 3.2% in the last week and up 31% over the past year, with earnings forecasted to grow by 16% annually. In such a dynamic environment, identifying high growth tech stocks inv…
Tenaya Therapeutics, Inc. One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-2…
The United States market remained flat over the last week, yet it has seen a significant rise of 28% over the past year, with earnings expected to grow by 16% annually. In this environment, identifying high growth tech stocks involves look…
The United States market has remained flat over the last week, yet it has shown a robust 28% increase over the past year with earnings expected to grow by 16% annually. In such an environment, identifying high growth tech stocks that align…
In the last week, the United States market has stayed flat, yet it has experienced a significant rise of 28% over the past 12 months, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth pot…
The United States market has remained flat over the last week, yet it has shown a notable rise of 29% over the past 12 months with an expected annual earnings growth of 16%. In this context, identifying high-growth tech stocks involves loo…
The United States market has shown impressive growth, with a 28% increase over the past year despite remaining flat last week, and earnings are projected to grow by 16% annually. In this context, identifying high-growth tech stocks involve…
In the last week, the market has stayed flat, yet it is up 30% over the past year with earnings forecast to grow by 16% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate stro…
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya’s Work with Patients to Advance Gene Therapy and Early-…
The United States market has shown a robust performance, rising 1.7% over the last week and climbing 34% over the past year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks…
Over the last 7 days, the United States market has risen 1.9%, contributing to a 24% increase over the past year, with earnings forecasted to grow by 15% annually. In such a dynamic environment, identifying high growth tech stocks involves…
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. Andy Hsieh of William Blair maintained a Buy rating on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) on March 12, expressing a positive outloo…
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 12, 2026, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), in line with the (12c) consensus estimate. CEO Faraz Al…
In early March 2026, Tenaya Therapeutics reported a reduced full-year net loss of US$90.6 million and highlighted encouraging preclinical and Phase 1 data for its HDAC6 inhibitor TN-301 in Duchenne muscular dystrophy and cardiomyopathy, al…
Tenaya Therapeutics, Inc. Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports TN-301’s…
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated Mechanism and Opportuni…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya…
(RTTNews) - Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY), to discover human genetic targets for the potential development of disease-modifying treatments for cardiovascular dis…
Tenaya Therapeutics, Inc. Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfron…
Tenaya Therapeutics Inc. (NASDAQ:TNYA) is one of the overlooked growth stocks to buy. On January 8, Morgan Stanley lowered the firm’s price target on Tenaya Therapeutics to $2 from $5 and kept an Overweight rating on the shares. In a secto…
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is one of the stocks under $1 that will explode.Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech Chaikom/Shutterstock.com On Januar…
(RTTNews) - Tenaya Therapeutics, Inc. (TNYA) Friday announced that it has priced a $60 million public offering of 50 million units at $1.20 per unit. Each unit consists of one share of common stock and a warrant to purchase one share at $1…
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the…
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the…
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patients…
[Heart, stethoscope and EKG] MarsBars/E+ via Getty Images Tenaya Therapeutics (TNYA [https://seekingalpha.com/symbol/TNYA]) stock fell after its mid-stage trial for TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy, w…